ArchiveExpertREACT - Adolescent & Meningococcal Vaccines
New Meningitis B Vaccines - Does the Best Science Matter?
At the 2009 Meningitis Research Foundation meeting, both Wyeth and Novartis claimed superior science for their MenB approaches - but in vaccine markets, the best science does not always win.

John SavopoulosGroup Director, VacZine Analytics · November 2009Ph.D, MBA · 20+ years vaccine market intelligence
Meningitis BMenB VaccineNovartisWyethSerogroup BVaccine Science
Editor's note: This article was originally distributed as a view-only briefing as part of the ExpertREACT service by VacZine Analytics.
In terms of current meningococcal disease burden, the statistics related to serogroup B are convincing when making arguments in support of new meningitis vaccines........... CONTINUED......